The solid-phase enzyme immunoassay (EIA) for HBsAg2, described by Wolters et al. (1976) , has a similar sensitivity as a commercially available sandwich-type solid-phase radioimmunoassay (RIA). In the same paper, a method for the confirmation of presumptive positives was described. As this method is laborious, we have attempted to develop a simpler one, which is based on the in situ blocking of the antigen bound to the solid-phase antibody by human antibodies against HBsAg (anti-HBs). Essentially the same principle has also been reported for the specificity control of presumptive positives in RIA (Ling et al., 1975) .
Human anti-HBs is often preferred as neutralising antibody because the risk of neutralising nonspecifically reacting factors is small. However, one must be sure that HBsAg of one subtype, for example, ay, will be neutralised by antibodies against the other subspecificity (ad) or by antibodies directed only against the main antigenic determinant a. We describe the results obtained with two different human anti-HBs sera comparing the two different specificity control methods mentioned above.
Material and methods
Two human anti-HBs sera were used in this study. One had the subspecificity of anti-ay as demonstrated by immunodiffusion. The subspecificity of the other anti-HRB8 serum could not be determined by this technique. Both antisera were further characterised by determining the highest dilution that still reduced the reaction of HB8Ag of either subtype in EIA. It was found, for the anti-ay serum, that the ratio ' if the colour developed in well I was weaker than in wells II and III, the sample was regarded as specific positive; if the colour developed in all four wells was equally intensive (and weak), the sample was regarded as false positive; if no colour developed in any of the four wells the sample was also regarded as false positive ('repeat negative'). All other combinations of colours rendered an inconclusive result. When read colorimetrically, the percentage of neutralisation in well I was calculated by the same formula as described above.
The total amount of antibody used per test sample was about the same for both methods.
Both methods were studied with two sera containing HB8Ag, one of the ay subtype and the other of the ad subtype. Serial dilutions were made in 0-9 % NaCl (or 0-9% NaCl containing 0-1 % bovine serum albumin). The concentration of HB.Ag was determined using the German Reference Panel for HB8Ag as a standard (Gerlich et al., 1976) and was 99-4,g/ml for ay and 13 -7 g/ml for ad. Each of these serum dilutions was neutralised with both human anti-ay and anti-ad. Thirty sera found to be presumptively positive in EIA screening (all of them with low and intermediate HBsAg contents) were subjected to specificity control by the in situ blocking method using human anti-ad, and also tested by radioimmunoassay (Ausria II), according to the manufacturer's instructions (Abbott Laboratories, North Chicago, Ill, USA). The results are given in Table 2 .
Discussion
The results in Table 1 demonstrate that the 'blocking' method is superior to the 'dilution' method.
By eye reading in the 'dilution' method one would be unable to draw a conclusion if the HBsAg concentrations were above a certain level (about 3 jug/ml). However, eye reading in the 'blocking' method did not present any difficulty for drawing a conclusion at any of the concentrations tested.
Colorimetrically determined percentages of neutralisation in the 'dilution' method are also lower than those obtained in the 'blocking' method. Thus, the highest concentration of ay neutralised in the 'dilution' method by at least 50 % (neutralised with anti-ay) is between 0-2 and 0-4 ,ug/ml; for the ad subtype it is a concentration of 0-2 ,ug/ml. In the 'blocking' method (regardless of the antibody subspecificity) even the highest concentrations of HB%Ag tested had a percentage of neutralisation in excess of 50% (Table 1 ). The results of the 'blocking' method thus show a higher efficacy of neutralisation for both subtypes adand ay. A likely explanation is that in the 'blocking' method the solid-phase anti-HBs, which has a finite and relatively low capacity, binds only a fraction of the total quantity of HBsAg offered to it in the first incubation. The remaining unbound HBsAg is being discarded. The added anti-HBs (in relatively higher quantity per well than in the 'dilution' method) has, therefore, an 'easier' task in neutralising (blocking) the HB8Ag bound to the solid phase. Both 'dilution' and 'blocking' methods gave similar results by eye reading only when the concentration of HBsAg in the samples was low (below 0-2 ,g HB8Ag/ml).
Economy of time and reagent is also important. At least 2 x 6 dilutions of the sample and extra undiluted sample are needed for the 'dilution' method, thus occupying 13 reagent-wells per sample. Strong positives might not reach an endpoint so that even further dilution and retesting are necessary.
The 'blocking' method is performed entirely in the antibody-coated microtitre plate and the number of wells per sample is only three.' While in both lInstead of two separate wells for antibodies with different subspecificities, as described here, only one well is used in the routine work. methods about the same quantity of neutralising antibody per sample is used, a saving factor of about four with regard to the remaining reagents is obtained by the 'blocking' method.
The data presented in Table 1 show that the anti-ay was slightly more effective in neutralising the ay subtype than ad and vice versa. However, it is evident that both antisera studied here can be used equally well for neutralisation of both subtypes in the 'blocking' method.
Most of the specificity control results obtained with the 'blocking' method agreed with the RIA results ( Table 2) . Disagreements were encountered in four cases (Nos. 2, 4, 5, and 13 in Table 2 ). There is no practical possibility of finding the correct answer since at the moment no method superior in terms of sensitivity and specificity to both EIA and RIA exists.
For a multicentre clinical trial of the EIA method for HBsAg, which has just been completed, we have chosen the 'blocking' method for specificity control. The results of this trial will be published separately, but it is of interest to note here that. out of over 1100 cases in which presumptive positivity was found in screening, the 'blocking' method gave only 27 inconclusive results.
We conclude that the 'blocking' method is superior to the 'dilution' method for specificity control of the enzyme-immunoassay for HBsAg for the following reasons: the neutralisation procedure is more efficient; it is less laborious; it has a reagent-saving factor of about four.
One of the major problems in handling tissues for immunofluoresence is that they must be quickfrozen (Pearse, 1968; Nairn, 1969; Feltkamp-Vroom, 1975 We have devised a method for overcoming most of these problems that is easy, economical, and very efficient.
The principle of our procedure involves partially filling a one-litre thermos flask with the material' used by a number of companies to form refrigerator or ice packs. The nature of this material is a trade secret but apparently it is some sort of plastic and it is stated to be non-toxic and non-corrosive. In the centre of the flask a closely fitting chamber is created, using a template (Fig. 1) . For the template, a standard liquid scintillation counting vial (Wheaton Glass Co, Brampton, Ontario) wrapped several times with wax paper is used. A one-inch layer of the refrigerant is poured around this and is allowed to solidify in the freezer, thus allowing for expansion before subsequent layers are put on top of this. As can be seen, the top of the vial is left protruding above the surface so that it can easily be removed from the flask. The chamber can also be readily bored with a
